Ex Vivo Apoptosis in CD8+ Lymphocytes Predicts Rectal Cancer Patient Outcome

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left"> </td><td class="align_center">Number of patients</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">5FU + Oxaliplatin/5FU/5FU + Oxaliplatin reduced dose/5FU reduced dose</td><td class="align_center">67/12/5/3</td></tr><tr><td class="align_left">Surgery/inoperable/complete remission/rejected surgery</td><td class="align_center">76/8/2/1</td></tr><tr><td class="align_left">Radiotherapeutic dose (Gy): 50.4/45.0/55.8/10.8</td><td class="align_center">75/6/5/1</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Patients treatment by chemotherapy, surgery and radiotherapy.

Gastroenterology Research and Practice

tab1

Table 1

Table 1: Ex Vivo Apoptosis in CD8+ Lymphocytes Predicts Rectal Cancer Patient Outcome 